How India Exports Losartan to the World

In the United States, losartan is approved through Abbreviated New Drug Applications (ANDAs). For instance, TEVA Pharmaceuticals USA received approval for losartan potassium tablets (25 mg, 50 mg, and 100 mg) on October 6, 2010. Similarly, Apotex Corp. obtained approval for the same dosages on October 6, 2010. These approvals indicate a competitive market with multiple generic manufacturers.

The substantial number of Indian exporters (506) underscores India's significant role in supplying losartan to the U.S. market. However, manufacturers must adhere to stringent FDA regulations, including compliance with Current Good Manufacturing Practices (cGMP) and ensuring bioequivalence to the reference listed drug. Any deviations can result in import alerts or product recalls, emphasizing the importance of maintaining high-quality standards.

In the European Union, losartan is marketed under various brand names, such as Cozaar. The European Medicines Agency (EMA) has harmonized the summaries of product characteristics across member states to ensure consistent information. For example, on September 3, 2008, the EMA issued a decision to harmonize the product information for Cozaar. Manufacturers exporting to the EU must comply with EU Good Manufacturing Practice (GMP) guidelines, which are essential for obtaining and maintaining marketing authorizations.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of medicines. Losartan is subject to the same rigorous standards as in the EU. Notably, on October 23, 2025, the MHRA issued a Class 4 Medicines Defect Notification concerning losartan potassium/hydrochlorothiazide tablets due to labeling errors. This highlights the necessity for exporters to maintain strict quality control measures to prevent such issues.

Losartan is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The WHO's inclusion signifies the medication's efficacy, safety, and cost-effectiveness. Additionally, losartan must meet international pharmacopoeia standards, including those set by the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality and consistency of losartan products worldwide.

In India, losartan is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines, including losartan. Manufacturers must adhere to the ceiling prices set by the NPPA to ensure affordability. For exports, the Directorate General of Foreign Trade (DGFT) may require a No Objection Certificate (NOC) to ensure that domestic supply is not adversely affected by export activities.

The primary patents for losartan have expired, leading to a competitive market with multiple generic manufacturers. This has resulted in increased availability and reduced prices, benefiting consumers globally. However, manufacturers must ensure that their products do not infringe on any remaining secondary patents or exclusivities to avoid legal challenges.

In June 2021, the MHRA recalled certain batches of losartan-containing products due to contamination with a potentially carcinogenic impurity. This incident underscores the critical importance of stringent quality control measures in the manufacturing process.

In October 2025, the MHRA issued a Class 4 Medicines Defect Notification for losartan potassium/hydrochlorothiazide tablets due to labeling errors. While classified as a low-risk issue, it highlights the necessity for meticulous attention to detail in packaging and labeling to maintain compliance and ensure patient safety.

These developments emphasize the need for continuous vigilance and adherence to regulatory standards to maintain market access and protect public health.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). Approximately 70–80% of India's API and KSM requirements are imported from China, creating a significant dependency. This reliance is particularly concerning for drugs like Losartan, where the synthesis process depends on specific KSMs predominantly sourced from China. Any disruption in the supply of these materials can halt production, leading to shortages and increased costs.

Recent efforts to reduce this dependency include India's Production Linked Incentive (PLI) scheme, launched in 2025, which aims to bolster domestic manufacturing of critical KSMs and APIs. By 2025, 48 projects had been approved under the scheme, focusing on fermentation-based products like Penicillin G, which India had ceased producing decades ago. However, the effectiveness of these initiatives in mitigating risks for Losartan's supply chain remains to be seen.

The Losartan export market from India is notably concentrated. The top five exporters—Zydus Lifesciences Limited, Micro Labs Limited, Cipla Limited, Aurobindo Pharma Ltd, and Alembic Pharmaceuticals Limited—account for 44.6% of total exports, with Zydus Lifesciences Limited alone holding a 24.1% share. This concentration poses a risk, as disruptions affecting these key players could significantly impact the global supply of Losartan.

The PLI scheme, initiated in 2025, aims to diversify and strengthen India's pharmaceutical manufacturing base. While it has led to the approval of 48 projects focusing on critical APIs and KSMs, the scheme's impact on reducing supplier concentration in the Losartan market is still unfolding.

Geopolitical tensions and shipping disruptions pose additional risks to the Losartan supply chain. The Red Sea and Strait of Hormuz are critical maritime routes for pharmaceutical exports. Any instability in these regions can delay shipments and increase costs. Furthermore, U.S.-China trade tensions have led to increased scrutiny of Chinese API production, especially following contamination incidents in 2019 involving "sartan" APIs, including Losartan. The Defense Health Agency highlighted the national security risks of increased Chinese dominance in the global API market, emphasizing the need for diversified sourcing strategies.

• Diversify API and KSM Sources: Reduce reliance on Chinese imports by developing alternative suppliers in other countries and enhancing domestic production capabilities.

• Strengthen Supplier Vetting and Monitoring: Implement rigorous quality control measures and continuous monitoring of suppliers to detect and address potential issues promptly.

• Enhance Inventory Management: Maintain strategic stockpiles of critical APIs and KSMs to buffer against supply disruptions.

• Invest in Advanced Manufacturing Technologies: Adopt innovative manufacturing processes to improve efficiency and reduce dependency on imported raw materials.

• Develop Contingency Plans: Establish comprehensive risk management strategies to address potential geopolitical and logistical disruptions.

RISK_LEVEL: HIGH